Capital International Sarl Acquires 78,792 Shares of The Cooper Companies, Inc. $COO

Capital International Sarl raised its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 72.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,857 shares of the medical device company’s stock after acquiring an additional 78,792 shares during the quarter. Capital International Sarl owned approximately 0.09% of Cooper Companies worth $12,879,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital International Ltd. CA increased its position in Cooper Companies by 61.5% during the 3rd quarter. Capital International Ltd. CA now owns 114,124 shares of the medical device company’s stock worth $7,824,000 after purchasing an additional 43,479 shares in the last quarter. Capital International Inc. CA grew its stake in shares of Cooper Companies by 58.6% during the third quarter. Capital International Inc. CA now owns 96,156 shares of the medical device company’s stock worth $6,592,000 after buying an additional 35,539 shares during the last quarter. Capital Group Investment Management PTE. LTD. increased its holdings in shares of Cooper Companies by 75.4% during the third quarter. Capital Group Investment Management PTE. LTD. now owns 24,195 shares of the medical device company’s stock worth $1,659,000 after buying an additional 10,399 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Cooper Companies by 48.6% in the 3rd quarter. Bank of Montreal Can now owns 204,479 shares of the medical device company’s stock valued at $14,019,000 after acquiring an additional 66,875 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Cooper Companies by 4.2% during the 3rd quarter. Legal & General Group Plc now owns 1,277,538 shares of the medical device company’s stock valued at $87,588,000 after acquiring an additional 50,979 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Cooper Companies Price Performance

Cooper Companies stock opened at $75.82 on Tuesday. The firm has a market cap of $14.79 billion, a P/E ratio of 37.53, a P/E/G ratio of 2.13 and a beta of 1.02. The stock’s 50 day moving average is $81.98 and its 200 day moving average is $76.02. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the business earned $0.92 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Insiders (CEO, directors and other executives) purchased shares in recent months, reinforcing management confidence in the business and complementing continuing share repurchases — a constructive signal for investors. CooperCompanies Insiders Buy as Rebound Setup Forms
• Positive Sentiment: An unnamed report raised Cooper’s price target to $103, reflecting upside from current levels and highlighting bullish analyst conviction after the quarter and buyback activity. Cooper Companies (NASDAQ:COO) Price Target Raised to $103.00
• Neutral Sentiment: Analyst/education pieces (Zacks) reiterate Cooper as a longer-term value/quality healthcare name but flag the importance of monitoring international revenue trends — useful for longer-horizon investors but not immediate catalysts. Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Another Zacks piece recommends watching geographic/international revenue trends for their impact on estimates — informative but not an immediate driver. Investing in The Cooper Companies (COO)? Don’t Miss Assessing Its International Revenue Trends
• Negative Sentiment: Citigroup reduced its price target to $87, signaling caution from some institutional analysts despite the recent earnings beat; conflicting analyst views are likely contributing to short-term selling pressure. Citigroup Cuts Cooper Companies (NASDAQ:COO) Price Target to $87.00

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COO. Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the stock a “buy” rating in a report on Friday, December 5th. Piper Sandler restated an “overweight” rating and set a $94.00 price target (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Mizuho set a $100.00 price objective on Cooper Companies and gave the company an “outperform” rating in a research note on Friday, December 5th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Rothschild & Co Redburn lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $90.79.

Insider Activity

In other Cooper Companies news, Director Maria Rivas acquired 1,000 shares of the stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $82.13 per share, with a total value of $82,130.00. Following the transaction, the director owned 11,141 shares in the company, valued at approximately $915,010.33. The trade was a 9.86% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lawrence Erik Kurzius bought 2,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was acquired at an average price of $82.50 per share, with a total value of $165,000.00. Following the completion of the acquisition, the director owned 7,777 shares of the company’s stock, valued at $641,602.50. This represents a 34.62% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 16,014 shares of company stock worth $1,304,416. 2.08% of the stock is owned by insiders.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.